Best Available Copy

Fig. 1A DNA and Amino Acid Sequence of Variable Region of FR1-H7 Heavy Chain

Heavy chain variable region sequence (cDNA)

Heavy chain variable region sequence (amino acid)

MAEVQLVQSGAEVKKPGASVKVSCKVSGYTFTDYYMHWVQQAPGKGLEWMG LVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARDDYMD VWGKGTLVTVSSASTKGP Fig. 1B DNA and Amino Acid Sequence of Variable Region of FR1-H7 light Chain

Light chain variable region sequence (cDNA)

CTTGAAACGACACTCACGCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGAGA
AGGAGCCACCCTCTCCTGTAGGGCCAGTCAGAGTGTTAGCGGCAGTGCGTTG
GCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGATG
CATCCAGTAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGG
GGCAGACTTCAGTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTG
TATTCCTGTCAGCAATATGGTAGCTCACCTCTCACTTTCGGCCCTGGGACCAA
AGTGGATGTCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCAT
CTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTTGTGTCCTGCTGAATAAC
TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATT

Light chain variable region sequence (amino acid)

LETTLTQSPDTLSLSPGEGATLSCRASQSVSGSALAWYQQKPGQAPRLLIYDASS RATGVPDRFSGSGSGADFSLTISRLEPEDFAVYSCQQYGSSPLTFGPGTKVDVKR TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD

Fig. 1C CDRs For FR1-H7 Nucleic Acid Sequences

VH (human heavy chain subclass I)

CDR1 GACTACTACATGCAC

CDR2 CTTGTTGATCCTGAAGATGGTGAAACAATCTACGCAGAGAAGTTCCAGGGC

CDR3 GATGACTACATGGACGTC

VL (human kappa light chain subgroup III)

CDR1 AGGGCCAGTCAGAGTGTTAGCGGCAGTGCGTTGGCC

CDR2 GATGCATCCAGTAGGGCCACT

CDR3 CAGCAATATGGTAGCTCACCTCTCACT

Fig. 1D CDRs For FR1-H7 Amino Acid Sequences

VH (human heavy chain subclass I)

CDR1

DYYMH

CDR2

LVDPEDGETIYAEKFQG

CDR3

DDYMDV

VL (human kappa light chain subgroup III)

CDR1

RASQSVSGSALA

CDR2

DASSRAT

CDR3

•

QQYGSSPLT

Fig. 2A DNA and Amino Acid Sequence of Variable Region of FR1-A1 Heavy Chain

Heavy chain variable region sequence (cDNA)

Heavy chain variable region sequence (amino acid)

MAQVQLVQSGAEVKKPGSSVKVSCKASGQTFTGYYMHWVRQAPGQGLEWMG RIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGGDLGG MDVWGQG Fig. 2B DNA and Amino Acid Sequence of Variable Region of FR1-A light Chain

Light chain variable region sequence (cDNA)

CTTGAAATTGTGCTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGA GCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCGGCATAGTAATGGA TACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCT GATCTATTTGGCTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCA GTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGA TGTTGGGGTTTATTACTGCATGCAAGCTCTACAAATTCCTCCGACTTTCGGCC CTGGGACCAAAGTGGATATCAAACGAACTGTGGCTGCA

Light chain variable region sequence (amino acid)

LEIVLTQSPLSLPVTPGEPASISCRSSQSLRHSNGYNYLDWYLQKPGQSPQLLIYL ASNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQIPPTFGPGTKVD IKRTVAA

Fig. 2C CDRs For FR1-A1 Nucleic Acid Sequences

VH (human heavy chain subclass I)

CDR1 GGCTACTATATGCAC

CDR2 AGGATCATCCTATCCTTGGTATAGCAAACTACGCACAGAAGTTCCAGGGC

CDR3 GGAGGAGATCTGGGCGGTATGGACGTC

VL (human kappa light chain subgroup II)

CDR1 AGGTCTAGTCAGAGCCTCCGGCATAGTAATGGATACAACTATTTGGAT

CDR2 TTGGCTTCTAATCGGGCCTCC

CDR3 ATGCAAGCTCTACAAATTCCTCCGACT

Fig. 2D CDRs For FR1-A1 Amino Acid Sequences

VH (human heavy chain subclass I)

CDR1 GYYMH

CDR2 RIIPILGIANYAQKFQG

CDR3 GGDLGGMDV

VL (human kappa light chain subgroup II)

CDR1 RSSQSLRHSNGYNYLD

CDR2 LASNRAS CDR3 MQALQIPPT

Fig. 3




Fig. 4A




Fig. 4B




Fig. 5A




Fig. 5B




Fig. 6

FGF-2		. 20	20	
(ng/ml)		20	20	-
FR1-H7		20	-	20
(μg/ml)	-	30	-	30

Molecular weight marker




Fig. 7




Fig. 8A




Fig. 8B





Fig. 9



^{*13} gram mouse euthanized

Fig. 10




Fig. 11




Fig. 12A




Fig. 12B




Fig. 13




Fig. 14




Fig. 15A




Fig. 15B




Fig. 15C




Fig. 15D




Fig. 16




Fig. 17





Fig. 18



يتمر

Fig. 19




Fig. 20




Fig. 21




Fig. 22

FGF-2	50	50		
(ng/ml)	30	50	-	_ -
FR1-A1		40	40	
(μg/ml)	-	10	10	10 -

Fig. 23




Fig. 24




Fig .25




Fig. 26A




Fig. 26B




Fig 26C




Fig. 26D




Fig. 26E




Fig. 27A





Fig. 27B






Fig. 27C





Fig. 27D



FGGGTKLTVLG

111

Fig. 28A. FR1-4H antibody variable sequences

Heavy chain variable region sequence (cDNA)
(gamma heavy chain)

(gamma heavy chain)	
CAGGTGCAGCTGGAGTTTGGCCCAGGACTGGTGAAGCCTTCGGAGAC CCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACT GGAGCTGGATCCGGCAGCCCCCAGGGAAGGGA	50 100 150 200 250 300 350 372
Heavy chain variable region sequence (amino acid)	
QVQLVEFGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IYYSGSTNYNPSLKSRVAISVDTSKNQFSLKLSSVTAADTAVYYCAREYY YDSSGYYFYAFDIWGQGTTVTVSS	50 100 124
Light chain variable region sequence (cDNA)	
CTGCCTGTGCTGACTCAGCCCCCCTCAGCGTCTGGGACCCCCGGGCAGAG GGTCTCCATCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATG TATACTGGTACCAGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTTT AGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAA GTCTGGCACTTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAGGATG AGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTG TTCGGCGGAGGGACCAAGCTGACCGTCCTAGGT	50 100 150 200 250 300 333
Light chain variable region sequence (amino acid). (Lambda light chain)	
LPVLTQPPSASGTPGQRVSISCSGSSSNIGSNYVYWYQQLPGTAPKLLIF RNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWV	50 100

Fig. 28B. FR1-4H antibody variable sequence CDRs

CDR amino acid sequences

V_H:

CDR1 SYYWS

CDR2 YIYYSGSTNYNPSLKS

CDR3 EYYYDSSGYYFYAFDI

V_L:

CDR1 SGSSSNIGSNYVY

CDR2 RNNQRPS

CDR3 AAWDDSLSGWV

CDR nucleic acid sequences

V_H:

CDR1 AGTTACTACTGGAGC

CDR3 GAGTATTACTATGATAGTAGTGGTTATTACTTTTATGCTTTTGATATC

V_L:

CDR1 TCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATAC

CDR2 AGGAATAATCAGCGGCCCTCA

CDR3 GCAGCATGGGATGACAGCCTGAGTGGTTGGGTG

jį

Fig. 29




Fig. 30. Examples of FGFR small molecule inhibitors.


Indolinone derivatives:

Quinolinone derivatives:


Pyrimido-pyridine derivatives:

Fig. 31.

-	5 ng	5 ng	5 ng	5 ng	5 ng	5 ng
_	-	0.5 μΜ	0.2	0.1 μΜ	0.05	0.02 μM
	-				- 0.5 μM 0.2 0.1 μM	- 0.5 μM 0.2 0.1 μM 0.05



FGF	-	100 ng	100 ng	100 ng	100 ng
Pryimido-pyridines		-	0.1	0.03	0.01
derivative B			μM	μΜ	μM



This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ OTHER.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.